Various tumor model preclinical studies showed a synergy of increased apoptotic activity in combination of doxorubicin and bortezomib, and prevented anti-apoptotic activity which both the transcription factor NF-κB and the MKP-1 involved are observed (4). This evidence concerns the gene DUSP1 and neoplasm.